Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 9:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 249 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Healthy Infants Clear all
Completed No phase listed Observational

Genetic Disorders of Mucociliary Clearance in Nontuberculous Mycobacterial Lung Disease

NCT00368446
View directory record Official record
Conditions
Cystic Fibrosis, Pseudohypoaldosteronism, Nontuberculous Mycobacterial Infection, Chronic Granulomatous Disease, Primary Ciliary Dyskinesia
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years to 65 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Sep 3, 2026, 9:47 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Increasing Infant Preventive Health Service Delivery in an Inner City Population

NCT00221507
View directory record Official record
Conditions
Healthy
Interventions
Reminder-Recall-Outreach, Case Management, Patient Navigator
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
Not listed
Enrollment
823 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2010
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Sep 3, 2026, 9:47 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants

NCT02096263
View directory record Official record
Conditions
Poliomyelitis, Diphtheria, Haemophilus Influenzae Type b, Tetanus, Acellular Pertussis, Hepatitis B
Interventions
Infanrix hexa, Pediarix, ActHIB, Pentacel, Engerix-B, Infanrix, Hiberix, Prevnar13, Rotarix
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 12 Weeks
Enrollment
585 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
43
States / cities
Tucson, Arizona • Fayetteville, Arkansas • Anaheim, California + 38 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Sep 3, 2026, 9:47 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Bacille Calmette-Guerin (BCG) Vaccine for Immune Protection Against Infections

NCT04884308
View directory record Official record
Conditions
Cystic Fibrosis, Bronchiectasis Adult, Non-Tuberculous Mycobacteria
Interventions
BCG TICE Vaccine
Biological
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 9, 2025 · Synced Sep 3, 2026, 9:47 AM EDT
Completed No phase listed Observational

Lung Function and Structure in Healthy Infants and Infants With Recurrent Wheezing

NCT00507676
View directory record Official record
Conditions
Asthma, Wheezing, Infant
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
2 Months to 2 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 29, 2012 · Synced Sep 3, 2026, 9:47 AM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies

NCT07160244
View directory record Official record
Conditions
Healthy
Interventions
Multivalent Group B streptococcus vaccine, Placebo, Infanrix hexa, Prevenar 20, Pediarix, Prevnar 20, Infanrix
Biological
Lead sponsor
Pfizer
Industry
Eligibility
1 Day to 49 Years
Enrollment
6,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
119
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 57 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 3, 2026, 9:47 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Community-based Implementation of Adapted STAC

NCT06689930
View directory record Official record
Conditions
Blood Pressure, Hypertension, Pregnancy Related, Health Equity
Interventions
PDSA Cycles
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 3, 2026, 9:47 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Adhesive Tape Trauma Evaluation of a New Gentle Tape in Healthy Infant Subjects

NCT03470012
View directory record Official record
Conditions
Skin (FLACC Scores of Test Subjects) After Tape Removal
Interventions
Multi-Purpose Gentle Tape
Device
Lead sponsor
Solventum US LLC
Industry
Eligibility
6 Months to 4 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Broomall, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Sep 3, 2026, 9:47 AM EDT
Completed No phase listed Observational

Event Related Potentials in Infants and Adults

NCT00088712
View directory record Official record
Conditions
Healthy, Child Development
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
3 Months to 45 Years
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Sep 3, 2026, 9:47 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Development of the Eye Motor System During the First 7 Months of Life in Infants With and Without a Family History of Cross-Eye

NCT00001143
View directory record Official record
Conditions
Healthy, Strabismus
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 3, 2026, 9:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis

NCT06154447
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-828, Placebo, Itraconazole, Midazolam, Tezacaftor, VX-118, Deutivacaftor
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
12
States / cities
Hollywood, Florida • Orlando, Florida • Overland Park, Kansas + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 3, 2026, 9:47 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Establishing Fibroblast-Derived Cell Lines From Skin Biopsies of Patients With Immunodeficiency or Immunodysregulation Disorders

NCT00895271
View directory record Official record
Conditions
Primary Immunodeficiency, DOCK8, Virus Susceptibility
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 85 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 3, 2026, 9:47 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks

NCT02914184
View directory record Official record
Conditions
Infections, Rotavirus, Rotavirus Vaccines
Interventions
HRV PCV-free liquid vaccine, Rotarix
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 12 Weeks
Enrollment
1,612 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
19
States / cities
Birmingham, Alabama • Anaheim, California • Paramount, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2020 · Synced Sep 3, 2026, 9:47 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Goat or Cow Milk Based Infant Formula GMS

NCT06312059
View directory record Official record
Conditions
Growth
Interventions
Advance Infant Formula Powder, "Kendamil Cow milk test product, "Kendamil goat milk test product
Other
Lead sponsor
Kendal Nutricare Ltd
Industry
Eligibility
Up to 14 Days
Enrollment
409 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Sep 3, 2026, 9:47 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants

NCT05844423
View directory record Official record
Conditions
Pneumococcal Vaccines
Interventions
0.5 ml dose of 1.1 mcg VAX-24, 0.5 ml dose of PCV20, 0.5 ml dose of 2.2 mcg VAX-24, 0.5 ml dose of 2.2/4.4 mcg VAX-24
Biological
Lead sponsor
Vaxcyte, Inc.
Industry
Eligibility
42 Days to 89 Days
Enrollment
802 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
32
States / cities
Jonesboro, Arkansas • Madera, California • Tampa, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Sep 3, 2026, 9:47 AM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

SAD and MAD of Inhaled AR-501 in Health Adults and P. Aeruginosa Infected Cystic Fibrosis Subjects

NCT03669614
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Inhaled AR-501, Inhaled Placebo
Drug
Lead sponsor
Aridis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 49 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
25
States / cities
Tucson, Arizona • Long Beach, California • Denver, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2023 · Synced Sep 3, 2026, 9:47 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Effects of C-section Delivery on Infant Brain Development

NCT03277612
View directory record Official record
Conditions
Healthy
Interventions
Not listed
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Dec 19, 2023 · Synced Sep 3, 2026, 9:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Evaluate the Relative Bioavailability, Food Effect, and Dose Proportionality of a Granule Formulation of Vanzacaftor/Tezacaftor/Deutivacaftor(VNZ/TEZ/D-IVA)

NCT06299709
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VNZ/TEZ/D-IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Sep 3, 2026, 9:47 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers

Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers

NCT06397768
View directory record Official record
Conditions
RSV Immunization
Interventions
RSVt vaccine, Diphtheria, tetanus, pertussis, poliomyelitis , Haemophilus influenzae type b, and hepatitis B vaccine, Diphtheria, tetanus, pertussis, Haemophilus influenzae type b and poliomyelitis vaccine, Hepatitis B vaccine, Streptococcus pneumoniae vaccine, Rotavirus vaccine, Measles, mumps, and rubella vaccine, Varicella virus vaccine, Placebo
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 12 Months
Enrollment
2,226 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
66
States / cities
Birmingham, Alabama • Grand Bay, Alabama • Mobile, Alabama + 55 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Sep 3, 2026, 9:47 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Tolerance of Healthy Term Infants Fed Infant Formulas #3

NCT00977964
View directory record Official record
Conditions
Gastrointestinal Tolerance
Interventions
Experimental milk protein infant formula Process A, Experimental milk protein infant formula Process B, Experimental milk protein infant formula Process C, Experimental milk protein infant formula Process D, Experimental milk protein infant formula Process E, Experimental milk protein infant formula Process F
Other
Lead sponsor
Abbott Nutrition
Industry
Eligibility
Up to 8 Days
Enrollment
270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
15
States / cities
Dothan, Alabama • Plantation, Florida • St. Petersburg, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2010 · Synced Sep 3, 2026, 9:47 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

NCT06824194
View directory record Official record
Conditions
Pneumococcal Immunization
Interventions
PCV21 vaccine, Prevnar 20 vaccine, M-M-R II vaccine, Rotarix, RotaTeq, Vaxelis vaccine, Varivax, Priorix, VAQTA, Havrix
Biological
Lead sponsor
Sanofi
Industry
Eligibility
42 Days to 89 Days
Enrollment
2,360 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
103
States / cities
Birmingham, Alabama • Guntersville, Alabama • Oneonta, Alabama + 81 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 3, 2026, 9:47 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Growth of Healthy Term Infants Fed Formula Containing DHA-B

NCT02144402
View directory record Official record
Conditions
Growth, Tolerance, Infant Development
Interventions
infant formula with DHASCO, infant formula with DHASCO-B
Other
Lead sponsor
dsm-firmenich Switzerland AG
Industry
Eligibility
1 Day to 14 Days
Enrollment
159 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
10
States / cities
Dothan, Alabama • Jonesboro, Arkansas • Norwich, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2015 · Synced Sep 3, 2026, 9:47 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Bioavailability and Dosing of a Monosaccharide Supplement in Adults

NCT00782392
View directory record Official record
Conditions
Healthy Males
Interventions
Not listed
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
18 Years to 28 Years · Male only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated May 17, 2011 · Synced Sep 3, 2026, 9:47 AM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of QBW251 in Healthy Subjects and Cystic Fibrosis Patients

NCT02190604
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Placebo, QBW251
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
9
States / cities
Birmingham, Alabama • Denver, Colorado • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2020 · Synced Sep 3, 2026, 9:47 AM EDT